UltraGreen.ai Limited announced on Aug, 24 2026 that it has reaffirmed its long-term strategy and competitive positioning in the fluorescence-guided surgery market following recent regulatory approvals for new entrants in the United States indocyanine green (ICG) segment.

Chief Executive Officer Ravinder Sajwan said the company, which has operated in fluorescence-guided surgery for more than a decade, has expanded alongside the market and built its presence through an ecosystem that extends beyond supplying ICG dye.

Addressing shareholder concerns over new US competitors, Sajwan emphasised that Food and Drug Administration approvals do not automatically translate into commercial launches or market penetration. He added that UltraGreen.ai will tailor its response once rivals’ pricing, distribution and customer strategies become clearer.

The company highlighted its longstanding relationships with surgeons and key opinion leaders, support for teaching institutions and clinical research, and a record of reliable manufacturing and supply as core advantages in a safety-critical surgical environment.

UltraGreen.ai is broadening its portfolio to include a platform that combines dye, imaging and software for new clinical applications. Its PerfusionWorks software, which adds quantification and data capabilities, has completed its European Medical Device Regulation conformity assessment and is awaiting formal CE certification, after which US FDA clearance will be pursued.

Geographically, UltraGreen.ai’s regulatory approvals now span more than 43 countries across Europe, the Middle East and Asia, underpinning growth prospects beyond its established US business.

Sajwan underscored his confidence by noting his ongoing purchases of UltraGreen.ai shares, stating that he intends to increase his personal investment to align further with shareholders’ interests.

The company said it will continue to track competitive developments and update investors on any material changes.